" class="no-js "lang="en-US"> David Ezra - Medtech Alert
Sunday, September 14, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
David Ezra

David Ezra

About David Ezra

I work closely with clinicians and commissioners to ensure that services are locally customised and deliver significant efficiency savings. Passionate about the role of technology to support healthcare, I am proud of the huge impact of our solutions in reducing demand on secondary care services and delivering millions of pounds of efficiency savings to the NHS.

Related Story

Uncategorized

 The AI-powered Referral Solution to the UK’s Healthcare Problem | Pharmtech Focus

The AI-powered Referral Solution to the UK’s Healthcare Problem

December 1 2020

Vantage Health is delighted to announce that it has been acquired by Northgate Public Services […]